Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst

By: News Direct
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ: TLSA). Tiziana has disclosed plans to file INDs (Investigational New Drug applications) aiming to expand the clinical indications of its lead product, intranasal foralumab, into mild-to-moderate Alzheimer’s Disease (AD) and long COVID-19.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/tiziana-life-sciences-expansion-into-new-clinical-indications-proactive-research-analyst-254277864

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  254.41
+3.22 (1.28%)
AAPL  336.27
-0.73 (-0.22%)
AMD  544.58
-0.51 (-0.09%)
BAC  57.77
-0.41 (-0.70%)
GOOG  347.69
+4.01 (1.17%)
META  671.78
-10.53 (-1.54%)
MSFT  495.87
-1.88 (-0.38%)
NVDA  219.68
+0.34 (0.16%)
ORCL  148.31
-2.28 (-1.51%)
TSLA  364.47
-1.73 (-0.47%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.